Form 4: Xeris Biopharma Holdings Director Acquires Shares Following Milestone Achievement
SEC Form 4
Director Garheng Kong acquired 6,474 shares of Xeris Biopharma Holdings, Inc. common stock on March 15, 2024, due to the achievement of a Keveyis sales milestone.
Summary
- On March 15, 2024, Garheng Kong, a director of Xeris Biopharma Holdings, Inc., acquired 6,474 shares of common stock.
- This acquisition was a result of achieving the Keveyis Sales 2023 milestone, which triggered the settlement of a Contingent Value Right (CVR) in shares of Xeris Biopharma Holdings, Inc.'s Common Stock.
- The reporting person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on October 5, 2021, the effective time of the Merger.
- Following the transaction, Kong directly owns 114,144 shares of Xeris Biopharma Holdings, Inc.
- The number of shares of Common Stock for the CVR is equal to the product (A) $0.25 divided by the volume weighted average price for the Company's Common Stock as reported by Nasdaq for the ten (10) Trading Days immediately prior to October 5, 2021 and (B) the number of CVRs held by the holder as reflected on the CVR Register.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the director acquired shares due to a milestone achievement, indicating confidence in the company. However, it's a routine filing and doesn't necessarily signal a major shift in the company's outlook.
Positives
- The achievement of the Keveyis Sales 2023 milestone suggests positive performance for the drug.
- Director's acquisition of shares indicates confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of their confidence in the company's performance and future prospects.
Stakeholder Impact
- Shareholders may view the director's acquisition of shares as a positive signal.
- The achievement of the Keveyis sales milestone could positively impact employee morale.
Key Dates
| Date | Description |
|---|---|
| 05/24/2021 | Date of the transaction agreement among Xeris Pharmaceuticals, Inc., Strongbridge Biopharma plc, the Issuer (HoldCo) and Wells MergerSub, Inc. |
| 10/05/2021 | Effective time of the Merger, when the reporting person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable. |
| 03/15/2024 | Date of the transaction where Garheng Kong acquired 6,474 shares of common stock. |
| 04/01/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.